Tandem Diabetes Care (TNDM) said Tuesday that the US Food and Drug Administration has cleared its Control-IQ+ automated insulin delivery algorithm for use in adults with type 2 diabetes.
The technology is expected to be available in the US in March, Tandem said.
The approval was based on a clinical trial involving more than 300 participants with type 2 diabetes, comparing the use of Tandem's t:slim X2 pump with Control-IQ+ to multiple daily insulin injections, the company said.
The full trial results will be presented at a diabetes conference in March, Tandem added.
Tandem shares were more than 5% higher in recent trading.
Price: 34.30, Change: +1.64, Percent Change: +5.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.